TRCT
RVMD icon

Tower Research Capital (TRC)’s Revolution Medicines RVMD Stock Holding History

Tower Research Capital (TRC)’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$158K Sell
846
-2,865
-77% -$418K ﹤0.01% 1864
2026
Q1 		$361K Buy
3,711
+3,519
+1,833% +$355K 0.01% 1168
2025
Q4 		$15.3K Sell
192
-4,427
-96% -$290K ﹤0.01% 3296
2025
Q3 		$216K Sell
4,619
-66,915
-94% -$2.62M 0.01% 1399
2025
Q2 		$2.63M Buy
71,534
+61,199
+592% +$2.35M 0.07% 249
2025
Q1 		$365K Sell
10,335
-8,144
-44% -$331K 0.01% 1029
2024
Q4 		$808K Buy
18,479
+16,087
+673% +$812K 0.02% 744
2024
Q3 		$108K Sell
2,392
-23,662
-91% -$1.03M ﹤0.01% 2159
2024
Q2 		$1.01M Buy
26,054
+24,641
+1,744% +$921K 0.02% 766
2024
Q1 		$45.5K Sell
1,413
-7,132
-83% -$211K ﹤0.01% 2344
2023
Q4 		$245K Sell
8,545
-12,146
-59% -$292K ﹤0.01% 1935
2023
Q3 		$573K Buy
20,691
+17,746
+603% +$526K 0.02% 798
2023
Q2 		$78.8K Sell
2,945
-473
-14% -$11.6K ﹤0.01% 2226
2023
Q1 		$74K Buy
3,418
+1,481
+76% +$36.5K ﹤0.01% 2152
2022
Q4 		$46K Sell
1,937
-4,014
-67% -$85.3K ﹤0.01% 2418
2022
Q3 		$117K Sell
5,951
-368
-6% -$8.09K ﹤0.01% 2436
2022
Q2 		$123K Sell
6,319
-1,120
-15% -$21.8K ﹤0.01% 2125
2022
Q1 		$190K Sell
7,439
-44
-0.6% -$958 ﹤0.01% 1765
2021
Q4 		$188K Buy
7,483
+1,417
+23% +$39.9K ﹤0.01% 1818
2021
Q3 		$167K Buy
6,066
+1,847
+44% +$53.8K ﹤0.01% 1978
2021
Q2 		$134K Buy
4,219
+2,176
+107% +$75.9K ﹤0.01% 2193
2021
Q1 		$94K Sell
2,043
-1,820
-47% -$81.6K ﹤0.01% 2636
2020
Q4 		$153K Sell
3,863
-6,384
-62% -$252K ﹤0.01% 1959
2020
Q3 		$357K Buy
10,247
+7,420
+262% +$206K ﹤0.01% 2025
2020
Q2 		$89K Buy
+2,827
New +$88.9K ﹤0.01% 2561

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Tower Research Capital (TRC)'s RVMD Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Revolution Medicines (RVMD) stake by 77% in Q2 2026, selling an estimated $418K and leaving 846 shares worth $158K. The position accounts for ﹤0.01% of the portfolio, ranked #1864.

Tower Research Capital (TRC) first reported a position in RVMD in Q2 2020 and has held it in 25 quarters since. The position peaked at $2.63M in Q2 2025. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Tower Research Capital (TRC) held 846 shares of Revolution Medicines worth $158K as of Q2 2026.
  • Tower Research Capital (TRC) sold 2,865 Revolution Medicines shares in Q2 2026, an estimated $418K.
  • Revolution Medicines made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1864 holding.
  • Tower Research Capital (TRC) first reported a position in Revolution Medicines in Q2 2020 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Revolution Medicines position peaked at $2.63M in Q2 2025.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.